All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-07-25T14:07:18.000Z

Positive topline results from the AGAVE-201 trial of axatilimab

Jul 25, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in chronic GvHD.

On July 24, 2023, positive topline results were announced from the AGAVE-201 trial of axatilimab, an investigational anti-colony-stimulating factor 1 receptor (CSF-1R) antibody, which was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) in 2021. Results from a phase I/II trial of axatilimab in patients with chronic graft-versus-host disease (cGvHD) have been previously reported by the GvHD Hub, it has also shown macrophage reduction in pre-clinical models.

AGAVE-201, a phase II dose-escalation study, enrolled 241 pediatric and adult patients with refractory or recurrent cGvHD who have experienced disease progression after two previous lines of therapy. Across all three dosing cohorts (0.3 mg/kg every 2 weeks, 1 mg/kg every 2 weeks, and 3 mg/kg every 4 weeks), the primary endpoint of objective response by Cycle 7 Day 1 was achieved, with 74%, 67%, and 50% of patients achieving an overall response within the first 6 months, respectively.

Common adverse events were fatigue and increased aspartate aminotransferase, blood creatine phosphokinase, lipase, blood lactate dehydrogenase, and alanine aminotransferase. Overall, 42.3% of patients experienced a serious adverse event, with 15.5% of patients discontinuing the study due to adverse events.

It is predicted that a Biologic License Application for axatilimab will be filed later this year, with a phase III trial expected to follow.

  1. Yahoo!finance. Syndax and incyte announce positive topline results from the pivotal AGAVE-201 trial of axatilimab in chronic graft-versus-host disease. https://finance.yahoo.com/news/syndax-incyte-announce-positive-topline-110000145.html Published July 24, 2023. Accessed July 25, 2023.

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox